BJH - volume 10, issue 6, october 2019
E. Van Valckenborgh PhD, M. Bakkus PhD, E. Boone PhD, A. Camboni MD, PhD, J-P. Defour PhD, B. Denys MD, H. Devos MD, L. Dewispelaere MD, G. Froyen PhD, A. Hébrant PhD, P. Heimann MD, PhD, P. Hermans MD, PhD, E. Heylen PhD, K. Jacobs PhD, F. Lambert MD, M. Le Mercier Apr, PhD, E. Lierman PhD, H. Louagie MD, PhD, B. Maes MD, PhD, M-B. Maes PhD, G. Martens MD, PhD, L. Michaux MD, PhD, F. Nollet PhD, MSc, H.A. Poirel MD, PhD, G. Raicevic PhD, P. Saussoy MD, PhD, T. Tousseyn MD, PhD, M. Van Den Bulcke PhD, P. Vandenberghe MD, PhD, K. Vandepoele PhD, P. Vannuffel PhD, T. Venken PhD, K. Vermeulen PhD
Molecular diagnostics have an increasing impact on diagnosis, risk stratification and targeted treatment in haemato-oncology. In the framework of a pilot study for the implementation of next-generation sequencing in the Belgian healthcare system, the Commission of Personalised Medicine was founded to give professional and evidence-based advice on the molecular analysis in haemato-oncology. This paper describes its recommendations for NGS analysis in myeloid malignancies. In addition, the minimally required set of genes that must be analysed is defined and algorithms for molecular workflow in myeloid malignancies are proposed.
(BELG J HEMATOL 2019;10(6):241–9)
Read moreBJH - volume 9, issue 6, november 2018
P. Heimann MD, PhD, H.A. Poirel MD, PhD
It is now well demonstrated that cytogenetic and molecular testing are valuable tools for the diagnostic, prognostication, and decision of treatment strategy in lymphoproliferative disorders. Here, we will give an overview of the genetic tests that represent current and future clinical assessment tools in the context of lymphoid malignancies. This review has been divided into two distinct but complementary parts. Part I will address the genetic aspects of low grade B-cell lymphomas and will very briefly describe the different technical methods that can be used in routine practice for the clinical management of lymphoid malignancies. Part II will cover aggressive B- and T/NK-cell lymphomas as well as Hodgkin lymphoma and will be published subsequently.
(BELG J HEMATOL 2018;9(6):225–36)
Read moreBJH - 2018, issue Abstract Book BHS, february 2018
S. Dupriez , A. Ferrant , M.C. Vekemans MD, B. Brichard MD, PhD, L. Michaux MD, PhD, T. Connerotte MD, E. Van den Neste MD, PhD, C. Vermylen , L. Knoops MD, PhD, C. Graux MD, PhD, F. Duhoux MD, PhD, C. Lambert MD, PhD, X. Poiré MD, PhD, H.A. Poirel MD, PhD
BJH - 2018, issue Abstract Book BHS, february 2018
H.A. Poirel MD, PhD, T. Vandendael , F. Calay , K. Henau , L. Van Eycken
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
